SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study

SARS CoV-2 in tumor tissue in glioblastoma patients – preliminary study

SARS-CoV-2 infection often causes neurological disorders. Experimental studies on an animal model have shown that SARS-CoV-2 is able to cross the blood-brain barrier. Researchers have also discovered that SARS-CoV-2 can infect glial cells. Gliomas are the most common type of brain tumor. Oncological...

Full description

Saved in:

Bibliographic Details
Main Authors:	Brzozowski Michal, Kolesnik Marcin, Michalski Aleksander, Drop Katarzyna, Polz-Dacewicz Malgorzata
Format:	Article
Language:	English
Published:	Sciendo 2024-12-01
Series:	Current Issues in Pharmacy and Medical Sciences
Subjects:	sars-cov-2 glioblastoma sars-cov-2 antibody covid-19
Online Access:	https://doi.org/10.2478/cipms-2024-0035
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of SARS-COV-2 vaccines in breast cancer patients : Egyptian experience
by: Mira Canaan, et al.
Published: (2024-05-01)

Serological insights from SARS-CoV-2 heterologous prime and boost responses in Thailand
by: Daniel Ward, et al.
Published: (2025-01-01)

Seroprevalence of SARS-CoV-2 Infection Among People Living with HIV in Libreville, Gabon
by: Samira Zoa-Assoumou, et al.
Published: (2024-12-01)

Dynamics of cytokine and antibody responses in community versus hospital SARS-CoV-2 infections
by: Tulika Singh, et al.
Published: (2024-11-01)

Immune evasion after SARS-CoV-2 Omicron BA.5 and XBB.1.9 endemic observed from Guangdong Province, China from 2022 to 2023
by: Huan Zhang, et al.
Published: (2024-11-01)

Evaluation of SARS-CoV-2 seroprevalence among clinical laboratory workers and its association with past exposure to infection and vaccination
by: Humaira Ahmed, et al.
Published: (2024-12-01)

Broad‐Spectrum Engineered Multivalent Nanobodies Against SARS‐CoV‐1/2
by: Zhihong Wang, et al.
Published: (2024-12-01)

Clinicopathological Features of Cutaneous Findings of SARS-CoV-2 Infection
by: Bengu COBANOGLU, et al.
Published: (2022-09-01)

Reflections on COVID-19: A Literature Review of SARS-CoV-2 Testing
by: Chin Shern Lau, et al.
Published: (2024-12-01)

Development of the test kit for detection of SARS-CoV-2 antibodies in sera of susceptible animals
by: M. A. Volkova, et al.
Published: (2021-07-01)

Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development
by: Xinkang Huan, et al.
Published: (2024-11-01)

Seroepidemiological study of the prevalence of SARS-CoV-2 antibodies (IgG and IgM) positive titers in the population, referring to the laboratories of Urmia city
by: Mohammad Hassan Ansari, et al.
Published: (2024-11-01)

Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain)
by: Ana C. Montagud, et al.
Published: (2025-01-01)

Effectiveness of COVID-19 vaccination among patients hospitalized from April 2020 to March 2021: A Retrospective cohort study
by: Nehal Khater, et al.
Published: (2024-05-01)

Seroprevalence of IgG Anti-SARS-CoV-2 among Voluntary Blood Donors in Dubai: Demographic and Risk Factors
by: May Raouf, et al.
Published: (2021-07-01)

Fc-binding nanodisc restores antiviral efficacy of antibodies with reduced neutralizing effects against evolving SARS-CoV-2 variants
by: Jaehyeon Hwang, et al.
Published: (2025-01-01)

Sustained applicability of SARS-CoV-2 variants identification by Sanger Sequencing Strategy on emerging various SARS-CoV-2 Omicron variants in Hiroshima, Japan
by: Chanroth Chhoung, et al.
Published: (2024-11-01)

Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variants
by: Léa Dépéry, et al.
Published: (2025-01-01)

MODES OF SARS-COV-2 TRANSMISSION
by: Nilesh D. Patel, et al.
Published: (2021-07-01)

Evaluation of The Anti-Viral Response Against SARS-CoV-2 Omicron Variant Appeared In The First Half of 2024 in Healthcare Workers Using In Vitro Cell Culture Model
by: Arzuhan Buyuker, et al.
Published: (2024-12-01)

Genomic Diversity and Evolution of Identified SARS-CoV-2 Variants in Iraq
by: Ahmed A. Al-Mankhee, et al.
Published: (2024-11-01)

Idiopathic Multicentric Castleman Disease following SARS-CoV-2 Vaccination
by: Chien-Yu Ker, et al.
Published: (2023-07-01)

Vaccination caused an underestimation of the cumulative incidence of SARS-CoV-2 infection
by: Nana Owusu-Boaitey
Published: (2025-02-01)

Is The SARS-CoV2 Evolved in Human Being: A prospective Genetic Analysis
by: Salvatore Dimonte, et al.
Published: (2020-12-01)

Cross-neutralization of Influenza A by SARS-CoV-2 specific neutralizing antibodies and polyclonal plasma: Is pre-exposure to SARS-CoV-2 protective against Influenza A?
by: Mohammad Mamun Alam, et al.
Published: (2024-12-01)

Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough
by: Yichuan Yao, et al.
Published: (2025-01-01)

SARS-CoV-2 infection induces human milk antibodies capable of mediating multiple functional activities
by: Jared Sheehan, et al.
Published: (2024-12-01)

Seroprevalence of SARS-CoV-2 in Children Admitted to a Pediatric Ward of an Urban Hospital
by: Rama Kaja, et al.
Published: (2022-12-01)

Computational analysis of SARS-CoV-2, SARS-CoV, and MERS-CoV genome using MEGA
by: Vipan Kumar Sohpal
Published: (2020-09-01)

Amino Acids Composition of Non-Structural Protein in SARS-CoV-2 the Cause of COVID-19 Pandemic
by: Suprianto Suprianto, et al.
Published: (2021-01-01)

Pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2 among female sex workers in Dakar, Senegal
by: Bobby Brooke Herrera, et al.
Published: (2025-01-01)

Comparative Analysis of Host Cell Entry Efficiency and Neutralization Sensitivity of Emerging SARS-CoV-2 Lineages KP.2, KP.2.3, KP.3, and LB.1
by: Nianzhen Chen, et al.
Published: (2024-10-01)

Current Updates on Variants of SARS‐CoV‐ 2: Systematic Review
by: Mulat Erkihun, et al.
Published: (2024-11-01)

Bispecific antibodies provide broad neutralization of emerging beta-coronaviruses by targeting ACE2 and viral spikes
by: Minghui Li, et al.
Published: (2024-12-01)

Prevalence of SARS-CoV-2 antibodies at the University hospital Heidelberg and correlation with SARS-CoV-2 incidence
by: C. Bundschuh, et al.
Published: (2024-11-01)

Accurate predictions of SARS-CoV-2 infectivity from comprehensive analysis
by: Jongkeun Park, et al.
Published: (2024-12-01)

Cross-reactivity between dengue virus and SARS-CoV-2 antibodies: Confirmation study using specimens from dengue-infected patients before the COVID-19 pandemic
by: Siti Churrotin, et al.
Published: (2024-11-01)

Post‐COVID immunity in patients with solid tumor or hematological malignancies treated with SARS‐CoV‐2 monoclonal antibodies
by: Gilberto Sabino‐Santos, et al.
Published: (2024-12-01)

Unraveling the SARS-CoV-2 spike protein long-term effect on neuro-PASC
by: Filipe Menezes, et al.
Published: (2024-12-01)

Respiratory viruses and SARS-CoV-2 virus circulation in the provinces of Lucca and Massa Carrara during the 2022/2023 and 2023/2024 flu seasons
by: Veronica Cunsolo, et al.
Published: (2024-11-01)